{
    "nct_id": "NCT00931073",
    "title": "A Phase I, Open-Label, Three-Period, Fixed-Sequence Study To Estimate The Steady-State Effect Of Ketoconazole And Omeprazole On The Single-Dose Pharmacokinetics Of Dimebon [PF-01913539] In Healthy CYP2D6 EM And PM Subjects",
    "status": "COMPLETED",
    "last_update_time": "2009-11-17",
    "description_brief": "This study will evaluate the potential for a drug-drug interaction of Dimebon with ketoconazole and omeprazole, potent inhibitors of the drug metabolizing enzymes CYP3A4 and CYP2C19, respectively.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "N/A",
    "results": null,
    "target_category": "Cognitive enhancer",
    "drug": [
        "Dimebon (latrepirdine; PF-01913539)"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The compound Dimebon is latrepirdine (PF-01913539), an orally administered small-molecule (originally an antihistamine) that was developed and tested for improvement of cognition in Alzheimer\u2019s disease and Huntington disease rather than as a biologic aimed at amyloid or tau pathology. Proposed mechanisms include modulation of neurotransmitter receptors and mitochondrial effects rather than a targeted anti-amyloid/tau biologic action. \ue200cite\ue202turn0search8\ue202turn0search3\ue202turn0search7\ue201",
        "Act: Key extracted details from the trial description \u2014 this is a drug\u2013drug interaction (pharmacokinetic) study of Dimebon with ketoconazole (CYP3A4 inhibitor) and omeprazole (CYP2C19 inhibitor) in healthy subjects, confirming the investigational drug is a small molecule (PF-01913539) and the program context is cognitive benefit testing in AD. Phase II/III clinical programs evaluated its effects on cognition (ADAS-cog, MMSE, etc.). These facts support classification as a cognitive-enhancement candidate rather than a disease-targeted biologic. \ue200cite\ue202turn0search6\ue202turn0search3\ue202turn0search1\ue201",
        "Reflect: Classification check \u2014 the trial tests pharmacokinetics of a small-molecule investigational drug that was pursued for cognitive improvement in neurodegenerative disease and is not a monoclonal antibody, vaccine, or other biologic targeting core AD pathology. Although latrepirdine\u2019s mechanism is multi-modal and not fully settled, the most appropriate category is 'Cognitive enhancer'. Note: if the goal were to label disease-modifying small molecules that directly target amyloid/tau, this would not qualify; ambiguity remains about exact molecular targets, but that does not change the category assignment. \ue200cite\ue202turn0search2\ue202turn0search7\ue201"
    ],
    "agent_type": "R) Multi-target",
    "explanation_agent": [
        "Reason: Dimebon (latrepirdine; PF-01913539) is an orally active small molecule developed as a cognitive enhancer that has shown activity at multiple biological processes rather than a single, specific disease biomarker (e.g., amyloid or tau). Published studies and reviews describe multireceptor activity (serotonin, adrenergic, etc.), modulation of calcium channels, effects on mitochondrial function, and induction of autophagy/proteostasis\u2014i.e., several distinct mechanisms are reported. \ue200cite\ue202turn0search8\ue202turn0search12\ue202turn0search6\ue201",
        "Act: Key extracted facts from the trial description and literature: the trial tests pharmacokinetics of dimebon (PF-01913539) in healthy subjects (drug\u2013drug interaction with ketoconazole and omeprazole) and the compound is a repurposed antihistamine/small molecule pursued for cognitive benefit in AD/HD. Mechanistic studies show low affinity for classic AChE or NMDA antagonism at clinically relevant concentrations, but report multireceptor modulation, mitochondrial/mitochondrial permeability pore effects, L-type Ca2+ channel modulation, and stimulation of autophagy leading to altered APP/A\u03b2 handling in preclinical models. These multiple, non-exclusive mechanisms map to different CADRO categories (D: Neurotransmitter Receptors; J: Metabolism/Bioenergetics; I: Proteostasis), supporting a multi-target classification. \ue200cite\ue202turn0search1\ue202turn0search8\ue202turn0search3\ue202turn0search2\ue201",
        "Reflect: Given the documented multimodal actions across neurotransmission, mitochondrial/bioenergetic function, and autophagy/proteostasis, the most accurate CADRO assignment is R) Multi-target rather than a single-category pick. If one had to force a single primary category, Neurotransmitter Receptors (D) or Metabolism/Bioenergetics (J) could be defensible, but the evidence shows several distinct mechanisms sufficiently overlapping different CADRO domains to justify R) Multi-target. Confirming sources (selected web search results): - Review summarizing latrepirdine\u2019s multiple cellular effects. \ue200cite\ue202turn0search8\ue201 - Pharmacology study showing lack of significant AChE/NMDA action at cognition-relevant concentrations. \ue200cite\ue202turn0search1\ue201 - Preclinical reports of autophagy stimulation and effects on APP/A\u03b2 metabolism. \ue200cite\ue202turn0search3\ue202turn0search2\ue201 - Reports of changes in extracellular A\u03b2 and multi-receptor/mitochondrial effects. \ue200cite\ue202turn0search6\ue202turn0search12\ue201"
    ]
}